| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w10822 |
| 来源ID | Working Paper 10822 |
| Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process | |
| Ernst R. Berndt; Adrian H. B. Gottschalk; Tomas Philipson; Matthew W. Strobeck | |
| 发表日期 | 2004-10-11 |
| 出版年 | 2004 |
| 语种 | 英语 |
| 摘要 | Congress enacted and renewed the Prescription Drug User Fee Acts (PDUFA) in 1992, and renewed it in 1997 and 2002, mandating FDA performance goals in reviewing and acting on drug applications within specified time periods. In turn, the FDA was permitted to levy user fees on drug sponsors submitting applications to the FDA. While PDUFA mandated action or review times, its ultimate impacts on actual final drug approval times are unknown. We model and quantify the impact of PDUFA-I and II on drug approval times, since these approval dates are the ones most directly related to new medicines becoming available to benefit patients. In assessing the impacts of PDUFA on drug approval times, it is noteworthy that approval times were trending downwards at 1.7% percent per year prior to implementation of PDUFA. Assuming continuation of that time trend, approval times post-PDUFA would have fallen even in the absence of PDUFA. Our principal finding is that PDUFA accelerated this downward trend so that instead of a counterfactual 6% reduction in approval times from 24.2 to 20.4 months in absence of these acts between 1991 and 2002, there was an observed decline of about 42%, from 24.2 to 14.2 months, following implementation of PDUFA. Thus, of the total observed decline in approval times between 1991 and 2002, approximately two-thirds can be attributed to PDUFA. However, much of this impact occurred in the initial years between 1992 and 1997 (PDUFA-I) rather than during the subsequent 1997-2002 time frame (PDUFA-II). We discuss implications of these findings and how future research might quantify the social value of the observed acceleration in the FDA drug approvals. |
| 主题 | Health, Education, and Welfare ; Health ; Other ; Law and Economics ; Industrial Organization ; Industry Studies |
| URL | https://www.nber.org/papers/w10822 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/568455 |
| 推荐引用方式 GB/T 7714 | Ernst R. Berndt,Adrian H. B. Gottschalk,Tomas Philipson,et al. Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process. 2004. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w10822.pdf（234KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
